Reweighting the LEADER trial to mirror Veterans Affairs patients with type 2 diabetes produced larger liraglutide benefits than the original trial reported. At 3 years, the absolute reduction in major adverse cardiovascular events reached 4.6% (95% CI 2.2–7.0) versus 1.6% in LEADER, and the all-cause mortality reduction reached 2.9% (0.8–5.1) versus 0.9%. The authors describe the transported estimates as statistically consistent with the trial results.
The pattern is plausible: veterans carry heavier cardiovascular risk than typical trial enrollees, and absolute benefit from any preventive drug scales with baseline risk. LEADER already enrolled a high-risk group, so a bigger gain in an even sicker population fits what GLP-1 receptor agonists have shown elsewhere. The analysis only reweights existing trial data, so it estimates what the trial might have found in veterans without observing real veterans take liraglutide. It also rests on measured characteristics being enough to explain differences between populations, an assumption that cannot be verified. Wide confidence intervals and a mortality estimate whose lower bound approaches zero argue against reading the 4.6% figure as precise. Because this is a preprint that has not been peer reviewed, the numbers could shift. Overall, the work is confirmatory rather than paradigm-shifting: it strengthens the case that liraglutide's cardiovascular benefit holds, and may grow, in older, sicker, predominantly male patients, but it adds no new randomized evidence. Adults with type 2 diabetes and established cardiovascular disease can reasonably raise GLP-1 therapy with their clinician.